Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
October 21, 2016
WASHINGTON—Covington represented India-based Piramal Enterprises and its wholly owned Critical Care subsidiary in the UK in the acquisition of five anesthesia and pain management injectable products from Janssen Pharmaceutica NV, in an all cash deal for an upfront consideration of US$155 million, and up to an additional US$20 million.
The products to be acquired are five injectable versions of well-established Janssen brands, Sublimaze (fentanyl citrate), Sufenta (sufentanil citrate), Rapifen (alfentanil hydrochloride), Dipidolor (piritramide), and Hypnomidate (etomidate).
The Covington team included Ralph Voltmer, Nathan Ostrander, and Brian Yang (corporate); Adem Koyuncu, Sarah Cowlishaw, and David Dennis (commercial transactions and regulatory); Guy Dingley (tax); Kathleen Gallagher-Duff and Jeremy Hutcher (intellectual property); and Miranda Cole (competition).